EA201270597A1 - Соединения, модулирующие андрогеновые рецепторы - Google Patents

Соединения, модулирующие андрогеновые рецепторы

Info

Publication number
EA201270597A1
EA201270597A1 EA201270597A EA201270597A EA201270597A1 EA 201270597 A1 EA201270597 A1 EA 201270597A1 EA 201270597 A EA201270597 A EA 201270597A EA 201270597 A EA201270597 A EA 201270597A EA 201270597 A1 EA201270597 A1 EA 201270597A1
Authority
EA
Eurasian Patent Office
Prior art keywords
androgen receptors
compounds
compounds modulating
modulating androgen
formula
Prior art date
Application number
EA201270597A
Other languages
English (en)
Other versions
EA021170B1 (ru
Inventor
Герд Вольфарт
Олли Термякангас
Харри Сало
Ииса Хеглунд
Арья Карьялайнен
Пиа Кнууттила
Патрик Хольм
Сирпа Раску
Анниина Весалайнен
Original Assignee
Орион Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201270597(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Орион Корпорейшн filed Critical Орион Корпорейшн
Publication of EA201270597A1 publication Critical patent/EA201270597A1/ru
Publication of EA021170B1 publication Critical patent/EA021170B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

Описаны соединения формулы (I)где R-R, А, В и Е имеют значения, указанные в формуле изобретения, и фармацевтически приемлемые соли и их сложные эфиры. Соединения формулы (I) обладают полезностью в качестве ткань-селективных модуляторов андрогеновых рецепторов (SARM) и, в частности, могут использоваться в качестве лекарственных средств для лечения рака простаты и других связанных с AR состояний и заболеваний, где желательным является антагонизм AR.
EA201270597A 2009-10-27 2010-10-27 Соединения, модулирующие андрогеновые рецепторы EA021170B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515909P 2009-10-27 2009-10-27
PCT/FI2010/000065 WO2011051540A1 (en) 2009-10-27 2010-10-27 Androgen receptor modulating compounds

Publications (2)

Publication Number Publication Date
EA201270597A1 true EA201270597A1 (ru) 2012-10-30
EA021170B1 EA021170B1 (ru) 2015-04-30

Family

ID=43383475

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270597A EA021170B1 (ru) 2009-10-27 2010-10-27 Соединения, модулирующие андрогеновые рецепторы

Country Status (36)

Country Link
US (5) US8975254B2 (ru)
EP (5) EP2493858B1 (ru)
JP (1) JP5763083B2 (ru)
KR (2) KR101670299B1 (ru)
CN (2) CN105061313B (ru)
AR (1) AR078793A1 (ru)
AU (1) AU2010311299C1 (ru)
BR (1) BR112012008823B8 (ru)
CA (1) CA2777896C (ru)
CL (1) CL2012000772A1 (ru)
CO (1) CO6531494A2 (ru)
CY (2) CY2020010I2 (ru)
DK (3) DK3369732T3 (ru)
EA (1) EA021170B1 (ru)
ES (3) ES2678073T3 (ru)
GE (1) GEP20166472B (ru)
HK (1) HK1173442A1 (ru)
HR (3) HRP20140919T1 (ru)
HU (2) HUE039390T2 (ru)
IL (2) IL218586A (ru)
LT (3) LT3056485T (ru)
LU (1) LUC00154I2 (ru)
MX (1) MX2012004867A (ru)
MY (1) MY159924A (ru)
NL (1) NL301041I2 (ru)
NO (1) NO2020018I1 (ru)
NZ (1) NZ598747A (ru)
PE (1) PE20121058A1 (ru)
PL (3) PL3056485T3 (ru)
PT (3) PT3369732T (ru)
RS (3) RS57592B1 (ru)
SI (3) SI2493858T1 (ru)
SM (1) SMT201400138B (ru)
UA (1) UA109535C2 (ru)
WO (1) WO2011051540A1 (ru)
ZA (1) ZA201202655B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2719590C2 (ru) * 2015-04-09 2020-04-21 Орион Корпорейшн Способ получения антагонистов андрогенного рецептора и их промежуточных соединений

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007500A2 (de) * 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
ES2541295T3 (es) * 2011-04-21 2015-07-17 Orion Corporation Carboxamidas que modulan el receptor de andrógenos
EP2574607A1 (en) * 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE10 modulators
MY198666A (en) * 2012-03-15 2023-09-14 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
KR20140138931A (ko) * 2012-03-23 2014-12-04 니혼노야쿠가부시키가이샤 티아졸카르복사미드 유도체 및 그 사용 방법
RU2015101115A (ru) 2012-06-15 2016-08-10 Тайсо Фармасьютикал Ко., Лтд. Гетероароматическое циклическое производное с алкильной разветвленной цепью
SG11201501036RA (en) 2012-08-23 2015-03-30 Alios Biopharma Inc Compounds for the treatment of paramoxyvirus viral infections
CN102952095A (zh) * 2012-10-19 2013-03-06 盛世泰科生物医药技术(苏州)有限公司 一种2-羧酸乙酯-5-溴甲基噻唑的合成方法
EA038819B1 (ru) * 2013-08-21 2021-10-25 Алиос Биофарма, Инк. Противовирусные соединения
WO2015172196A1 (en) * 2014-05-13 2015-11-19 Monash University Heterocyclic compounds and use of same
MX2017009454A (es) 2015-01-20 2017-10-20 Arvinas Inc Compuestos y metodos para la degradacion dirigida de receptor de androgenos.
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3250554B1 (en) * 2015-01-30 2022-05-18 Orion Corporation A carboxamide derivative and its diastereomers in stable crystalline form
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
AU2016264220A1 (en) * 2015-05-18 2018-01-04 Translational Drug Development Llc Heterocyclic compounds as kinase inhibitors
EP3388428B1 (en) 2015-12-07 2021-08-04 Suzhou Sinovent Pharmaceuticals Company Five-membered heterocyclic amides wnt pathway inhibitor
CN107286094A (zh) * 2016-04-12 2017-10-24 常州爱诺新睿医药技术有限公司 一种bay-1841788与药用辅料的固体分散体及其制备方法
PL3495352T3 (pl) * 2016-08-26 2021-08-02 Crystal Pharmaceutical (Suzhou) Co., Ltd. Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11168058B2 (en) 2017-03-07 2021-11-09 Orion Corporation Manufacture of a crystalline pharmaceutical product
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
CN116396220A (zh) 2017-08-09 2023-07-07 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物
CN107602471B (zh) * 2017-09-22 2021-04-27 成都恒汇化成医药科技有限公司 一种达罗鲁胺的晶型制备方法
JP2021515040A (ja) * 2018-02-27 2021-06-17 サンド・アクチエンゲゼルシヤフト ダロルタミドの結晶形態ｉｉ
WO2020035880A1 (en) * 2018-08-13 2020-02-20 National Centre For Biological Sciences-Tifr Inhibitors to target hiv-1 nef-cd80/cd86 interactions for therapeutic intervention
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
EP3932908A4 (en) * 2019-02-27 2022-11-16 Shenzhen TargetRx, Inc. SUBSTITUTED PYRAZOLE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE
TW202114658A (zh) 2019-07-02 2021-04-16 芬蘭商奧利安公司 達洛魯胺之醫藥組成物
CN110590668A (zh) * 2019-07-17 2019-12-20 江苏君若医药有限公司 N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法
CA3148115A1 (en) 2019-08-08 2021-02-11 Laekna Limited Method of treating cancer
CN111116476A (zh) * 2019-12-27 2020-05-08 武汉九州钰民医药科技有限公司 制备抗肿瘤药物多拉米胺的方法
EP4149938A1 (en) 2020-05-11 2023-03-22 Orion Corporation Method for the preparation of androgen receptor antagonists and intermediates thereof
MX2023001823A (es) 2020-08-13 2023-03-13 Pfizer Terapia de combinacion.
CN111978534B (zh) * 2020-09-07 2022-05-31 陕西师范大学 一种含苯并咪唑液晶基元的侧链型液晶离聚物及其制备方法
CA3214316A1 (en) 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
CN113527208A (zh) * 2021-08-31 2021-10-22 江西金丰药业有限公司 一步法制备2-氯-4-（1h-吡唑-3-基）苯甲腈的方法
CN113861115A (zh) * 2021-09-10 2021-12-31 浙江师范大学 一种吡唑酰胺类衍生物及合成方法和应用
WO2023161458A1 (en) 2022-02-28 2023-08-31 Química Sintética, S.A. Crystalline form of darolutamide
WO2023194528A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
FR2656609B1 (fr) 1989-12-28 1992-03-27 Synthelabo Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.
US5578550A (en) 1993-10-08 1996-11-26 American Cyanamid Company Herbicidal oxadiazole carbonamide compounds
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
BR9914018A (pt) 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
AU2002360818A1 (en) * 2001-12-28 2003-07-24 Bayer Pharmaceuticals Corporation 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
US20050101657A1 (en) 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
WO2003057674A1 (en) * 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
WO2003073999A2 (en) * 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pini-modulating compounds and methods of use thereof
AR040149A1 (es) * 2002-06-07 2005-03-16 Novartis Ag Compuestos de aminoacetonitrilo, un proceso para su preparacion, composicion, y uso del compuesto
US20060122234A1 (en) * 2002-08-02 2006-06-08 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
DE10322108B4 (de) 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
EP1634874A4 (en) 2003-06-12 2008-04-02 Chugai Pharmaceutical Co Ltd imidazolidine
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
AU2005280908A1 (en) 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
EP1710237A1 (en) * 2005-04-08 2006-10-11 Bayer CropScience S.A. New heterocyclylethylbenzamide derivatives
NZ591119A (en) 2005-05-13 2012-08-31 Univ California Use of diarylhydantoin compounds for treating specific cancers
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
WO2007005887A2 (en) 2005-07-01 2007-01-11 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds, compositions and uses thereof
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
EP1960382A1 (en) * 2005-11-03 2008-08-27 ChemBridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
WO2008062878A1 (fr) * 2006-11-22 2008-05-29 Nihon Nohyaku Co., Ltd. Nouveau dérivé de pyrazole, agent de lutte contre des organismes nuisibles et utilisation de l'agent de lutte contre des organismes nuisibles
WO2008124000A2 (en) * 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
AU2008273017C1 (en) * 2007-06-29 2014-02-13 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as Raf kinase inhibitors
AR068813A1 (es) 2007-08-30 2009-12-09 Takeda Pharmaceutical Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
UY31736A (es) 2008-03-26 2009-11-10 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso
JP2011524894A (ja) * 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2719590C2 (ru) * 2015-04-09 2020-04-21 Орион Корпорейшн Способ получения антагонистов андрогенного рецептора и их промежуточных соединений

Also Published As

Publication number Publication date
US20190100536A1 (en) 2019-04-04
US8975254B2 (en) 2015-03-10
PT2493858E (pt) 2014-09-03
LTC2493858I2 (lt) 2022-03-25
LT3369732T (lt) 2021-06-25
AU2010311299B2 (en) 2014-07-17
RS62123B1 (sr) 2021-08-31
SI3369732T1 (sl) 2021-08-31
CA2777896C (en) 2017-05-23
EP3056485B1 (en) 2018-05-09
EP3056485A1 (en) 2016-08-17
AU2010311299C1 (en) 2023-02-02
BR112012008823A2 (pt) 2019-02-19
SI2493858T1 (sl) 2014-10-30
MX2012004867A (es) 2012-06-08
JP2013508447A (ja) 2013-03-07
CL2012000772A1 (es) 2012-08-24
NO2020018I1 (no) 2020-06-17
JP5763083B2 (ja) 2015-08-12
KR101654529B1 (ko) 2016-09-06
EP2754656A1 (en) 2014-07-16
US20120225867A1 (en) 2012-09-06
RS57592B1 (sr) 2018-11-30
LUC00154I2 (ru) 2021-02-17
LUC00154I1 (ru) 2020-05-19
US11046713B2 (en) 2021-06-29
EP3369732A1 (en) 2018-09-05
LTPA2020514I1 (lt) 2020-07-27
NL301041I2 (nl) 2020-09-14
US10118933B2 (en) 2018-11-06
WO2011051540A9 (en) 2011-06-23
ES2486263T3 (es) 2014-08-18
CN102596910B (zh) 2015-11-25
IL218586A (en) 2015-10-29
HK1173442A1 (zh) 2013-05-16
LT3056485T (lt) 2018-07-25
SI3056485T1 (en) 2018-08-31
WO2011051540A1 (en) 2011-05-05
AU2010311299A8 (en) 2012-06-14
CO6531494A2 (es) 2012-09-28
AR078793A1 (es) 2011-12-07
PE20121058A1 (es) 2012-08-18
US20170260206A1 (en) 2017-09-14
PL2493858T3 (pl) 2015-01-30
HRP20181229T1 (hr) 2018-10-05
EP3885340A1 (en) 2021-09-29
HUE039390T2 (hu) 2018-12-28
EP2493858A1 (en) 2012-09-05
US20200299307A1 (en) 2020-09-24
UA109535C2 (uk) 2015-09-10
ZA201202655B (en) 2012-12-27
KR20120102057A (ko) 2012-09-17
BR112012008823B1 (pt) 2021-01-12
CN105061313A (zh) 2015-11-18
EA021170B1 (ru) 2015-04-30
HRP20211180T1 (hr) 2021-10-15
CN102596910A (zh) 2012-07-18
RS53469B (en) 2014-12-31
PL3369732T3 (pl) 2021-12-06
CY2020010I1 (el) 2020-11-25
MY159924A (en) 2017-02-15
DK2493858T3 (da) 2014-09-08
US10711013B2 (en) 2020-07-14
EP3369732B1 (en) 2021-05-26
KR101670299B1 (ko) 2016-10-28
CY1124429T1 (el) 2022-07-22
US20150203479A1 (en) 2015-07-23
EP2493858B1 (en) 2014-07-02
WO2011051540A8 (en) 2012-04-19
PT3056485T (pt) 2018-07-31
IL238044A (en) 2016-07-31
CY2020010I2 (el) 2020-11-25
DK3056485T3 (en) 2018-07-30
HUE055528T2 (hu) 2021-12-28
PT3369732T (pt) 2021-07-06
PL3056485T3 (pl) 2018-12-31
CN105061313B (zh) 2017-07-18
SMT201400138B (it) 2014-11-10
NZ598747A (en) 2013-06-28
ES2877248T3 (es) 2021-11-16
CA2777896A1 (en) 2011-05-05
HRP20140919T1 (hr) 2014-11-21
AU2010311299A1 (en) 2012-04-12
DK3369732T3 (da) 2021-07-26
GEP20166472B (en) 2016-05-10
ES2678073T3 (es) 2018-08-08
KR20160105927A (ko) 2016-09-07
IL218586A0 (en) 2012-05-31
BR112012008823B8 (pt) 2021-05-25
US9657003B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
EA201270597A1 (ru) Соединения, модулирующие андрогеновые рецепторы
EA201391560A1 (ru) Карбоксамиды, модулирующие андрогенные рецепторы
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
EA201291282A1 (ru) Азотсодержащие гетероарильные соединения
EA201490406A1 (ru) Модуляторы ядерного транспорта и их применение
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201491623A1 (ru) Замещенные пирролидин-2-карбоксамиды
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
EA201000046A1 (ru) Замещенные имидазогетероциклы
EA028821B9 (ru) Соединения и способы для модуляции киназ, а также показания к их применению
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
EA201490419A1 (ru) Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания
EA201290880A1 (ru) Новые соединения - ингибиторы фермента
EA201490287A1 (ru) Новые замещенные производные индола в качестве модуляторов гамма-секретазы
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201270808A1 (ru) Новые формы рифаксимина и их применение
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA201390292A1 (ru) Ингибиторы деацетилазы на основе гидроксамата
EA201490031A1 (ru) Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA201391124A1 (ru) Новые бензодиоксолпиперазиновые соединения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

ND4A Extension of term of a eurasian patent